China One Step Closer To Global Standards For Drug Quality With Rollout Of New GMP Guidelines
This article was originally published in PharmAsia News
Executive SummarySHANGHAI - China's State FDA recently issued a note to provincial FDA offices to require pharma companies and active pharmaceutical ingredient producers to file a Common Technical Document when they submit manufacturing applications as an effort to improve drug quality and research and development work in China
You may also be interested in...
Last week, U.S. Vice President Joe Biden visited China, Japan, and South Korean during a six-day Asia trip. One of Biden’s goals in China was to strengthen collaboration between the two countries on food and drug safety as well as patent protection.